Skip to main content

Table 1 Patient demographic data, past history and individual renal and oncological outcomes

From: Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report

Kidney Biopsy Age range (yr) Gender BMI (kg/m2) Comorbidities Medications prior to renal IrAE Immunotherapy regimen Renal function 3m Oncological outcome
Yes 40-49 Male 25.1 Nil Nil Ipilimumab + Nivolimumab CKD 2 CR
Yes 50-59 Male 25.6 HTN Metoprolol 50mg twice daily, amdodipine 10mg daily Ipilimumab + Nivolimumab CKD 3a CR
Yes 60-69 Male 26.2 Nil Nil Ipilimumab + Nivolimumab CKD 2 PR
Yes 70-79 Male 29.2 HTN, BPH, nephrolithiasis, acquired hypopituitarism Thyroxine 100mcg daily, Prednisolone 10mg daily. Ipilimumab + Nivolimumab CKD 3a PR
Yes 70-79 Male 27.5 HTN, dyslipidaemia, IHD, BPH, GORD Quinapril 5mg daily, rosuvastatin 20mg daily, allopurinol 200mg daily, rabeprazole 20mg daily. Pembrolizumab + Epacadostat CKD 3a PD
Yes 70-79 Male 24.6 HTN, IHD, DM, Diverticular disease. Amitriptyline 50mg daily, telmisartan 40mg daily. Ipilimumab + Nivolimumab CKD 3a PD
Yes 70-79 Male 29.2 IHD, BPH, HTN Aspirin 100mg daily, clopidogrel 75mg daily, atorvastatin 20mg daily. Ipilimumab + Nivolimumab CKD 3b PD
Yes 60-69 Female 41.2 HTN, GORD, rectal cancer. Perindopril 2.5mg daily, rabeprazole 20mg daily. Ipilimumab + Nivolimumab CKD 3a CR
Yes 70-79 Male 28.5 Acquired hypopituitarism Hydrocortisone twice daily, thyroxine 100mg daily Ipilimumab + Nivolimumab CKD 4 CR
Yes 50-59 Male 26 Previous pulmonary embolus Nil Ipilimumab + Nivolimumab CKD 5 CR
Yes 80-89 Male 23 Idiopathic cardiomyopathy. PMR. Data not available Pendrolizumab CKD 3b SD
Yes 30-39 Male 27 Nil Nil Ipilimumab + Nivolimumab CKD 2 PD
No 40-49 Male 35.9 HTN, Obesity, Depression Perindopril 5mg daily, venlafaxine 75mg daily Ipilimumab + Nivolimumab CKD 2 CR
No 70-79 Male 28.1 T2DM, HTN, IHD, dyslipidaemia, smoker, BPH Quinapril 5mg daily, rosuvastatin 20mg daily, metformin 1000mg daily, gliclazide 60mg daily, dapaglifozin (unknown dose) daily. Ipilimumab + Nivolimumab CKD 3a PD
No 70-79 Female 31.6 HTN, dyslipidaemia Data not available Ipilimumab + Nivolimumab CKD 3a PD
No 70-79 Male 33 T2DM, HTN, dyslipidaemia, IHD, PVD, BPH, haemochromatosis, EtOH excess Aspirin 100mg daily, clopidogrel 75mg daily, perindopril 5mg daily, hydrochlorothiazide 12.5mg daily, amlodipine 10mg, atorvastatin 40mg daily. Ipilimumab + Nivolimumab CKD 3b CR
No 50-59 Male 31.3 Nil Data not available Pendrolizumab Full recovery PR
No 60-69 Male 27.8 HTN, CVA, cardiomyopathy. Bisoprolol 5mg daily Ipilimumab + Nivolimumab CKD 3a PR
No 70-79 Male 24.9 HTN, Seizures, Aspirin 100mg daily, irbesartan 150mg daily, alendronate, simvastatin 40mg daily, Omeprazole 20mg daily, monoxidine 200mcg daily. Ipilimumab + Nivolimumab CKD 3b CR
No 60-69 Male N/A Nil Nil Ipilimumab + Nivolimumab CKD 2 PR
No 70-79 Male N/A IHD, T2DM, dysllipidaemia. Candesartan 32mg daily, aspirin 100mg daily, clopidogrel 75mg daily, simvastatin 40mg daily, propanolol 80mg daily, Ranitidine 150mg daily Ipilimumab + Nivolimumab CKD3b CR
No 70-79 Male 27.5 Bladder Ca (sx), IHD, AF, DVT Aspirin 100mg daily, nicorandil 10mg daily, rosuvastatin 20mg. Pembrolizumab CKD 3a CR
No 80-89 Male N/A Bullous pemphigoid, DM, DVT, PVD, AF Apixaban 2.5mg twice daily, metformin 1000mg daily, rosuvastatin 20mg daily, pantoprazole 40mg daily, gliclazide 60mg daily. Nivolimumab CKD 3b PD
  1. HTN – hypertension, IHD – Ischemic Heart Disease, PVD – peripheral vascular disease, BPH – Benign prostatic hypertrophy, GORD – Gastro Oesophageal Reflux Disease, PE – pulmonary embolus, CA – cancer, T2DM – Type 2 diabetes mellitus, EtOH – alcohol excess, CVA – stroke, AF – atrial fibrillation, DVT – deep venous thrombosis, CKD – chronic kidney disease, CR – Complete remission. PR – partial remission. SD – Stable disease. PD = progressive disease
\